United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 16, 2019-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees (together, the “Awardees”).
View HTML
Toggle Summary Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China .
View HTML
Toggle Summary Endologix Receives IDE Approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration (" FDA
View HTML
Toggle Summary Endologix Reports Second Quarter 2019 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019 . “We are pleased with our second quarter results, as
View HTML
Toggle Summary Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019
IRVINE, Calif. --(BUSINESS WIRE)--Jul. 15, 2019-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2019 after the market close on Thursday, August 8,
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Jul. 11, 2019-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).
View HTML
Toggle Summary Endologix, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)--Jun. 17, 2019-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the 2019 BMO
View HTML
Toggle Summary Endologix Announces Reinstatement of CE Mark for its Nellix EndoVascular Aneurysm Sealing System
IRVINE, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been
View HTML
Toggle Summary Endologix Reports First Quarter 2019 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--May 2, 2019-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2019 . “Our first quarter financial and operational
View HTML
Toggle Summary Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019
IRVINE, Calif. --(BUSINESS WIRE)--Apr. 15, 2019-- Endologix, Inc.  (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019 .
View HTML
Toggle Summary Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants
The Company reports preliminary revenue for the first quarter ending March 31, 2019 of at least $35 million The Company reiterates financial guidance for 2019 Transactions expected to close on or about April 3rd Endologix management to host conference call today at 8:30 a.m. ET IRVINE, Calif.
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Mar. 20, 2019-- Endologix, Inc.  (Nasdaq:ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to nine newly hired employees (the “Awardees”).
View HTML
Toggle Summary Endologix Announces Approval of Reverse Stock Split
IRVINE, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX) previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019 , authorizing its Board of Directors to amend the Company's certificate of incorporation
View HTML
Toggle Summary Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 25, 2019-- Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018 .
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 11, 2019-- Endologix, Inc.  (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to eight newly hired employees (the “Awardees”).
View HTML